Navigation Links
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
Date:12/1/2008

-- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML --

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from its studies of voreloxin in acute myeloid leukemia (AML) will be presented during the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 5-9, 2008. Researchers will present updated interim data from the company's ongoing Phase 2 clinical trial of single-agent voreloxin (formerly SNS-595) for elderly patients with newly diagnosed AML and from its Phase 1b/2 study of voreloxin in combination with cytarabine for relapsed/refractory AML. In addition, results from the Phase 1 study of SNS-032, a selective inhibitor of cyclin dependent kinases 2, 7 and 9, in both chronic lymphocytic leukemia and multiple myeloma will be presented. Following are the details on each of these data presentations.

Sunday, December 7, 2008

Viewing: 9:00 a.m. to 8:00 p.m. PT

Presentation Time: 6:00 p.m. to 8:00 p.m. PT

Hall A, MosconeCenter

Abstract #1951

Title: "Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study)"

Poster Board II-45

Abstract #1955

Title: "Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia"

Pos
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
3. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
6. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
9. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., previously ... members to its Board of Directors, enhancing executive ... the company, a leading licensed producer of medicinal ... Bedrocan has 13 years, experience in producing and ... countries, including Canada. As previously ...
(Date:8/21/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ) today announced results ... Quarterly highlights 1   Operating results for the ... of fiscal 2014, and other achievements, include: , Worldwide ... , Strong international net sales of $13.2 million, an ... U.S. net product sales reached a new high of $58.8 ...
(Date:8/21/2014)... , Aug. 21, 2014 Asterias Biotherapeutics, Inc. ... field of regenerative medicine, announced today the appointments of ... Company,s newly expanded Board of Directors. With these additions, ... three of whom are independent. Andy ... with emerging growth companies. He is currently Managing Director ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
(Date:8/21/2014)... on her body in terms of how it can ... complete human being with thoughts and feelings. While objectification ... how does it affect individual romantic relationships? New research ... SAGE journal, finds that more objectification of a female ... pressure and coercion., Researchers Laura R. Ramsey and Tiffany ...
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... allege the blood thinner caused patients to suffer uncontrollable ... in U.S. courts, Bernstein Liebhard LLP reports. According to ... August 14th in U.S. District Court, Easter District of ... who died due to a bleeding event that was ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... “Home Audio Equipment (Product Types - Home Theatre in-a-box, ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 15.94 billion in 2012 and is expected ... a CAGR of 3.7% from 2013 to 2019. Europe ...
(Date:8/21/2014)... American Addiction Centers, a leading national provider ... drug and/or alcohol addiction, has been named to the ... , The company is ranked 7th on the “Top ... on the list in the “Nashville Metro Area” sub-category. ... Addiction Centers (AAC) ascended to number 474 on the ...
(Date:8/21/2014)... Sasha is a 10 year old Alaskan malamute, and ... older, and is having trouble getting up and down, and ... an owner who purchased a Butler Mobility Inclined Platform Wheelchair ... no longer get up and down the stairs from main ... had tried a stair lift, but had to transfer from ...
Breaking Medicine News(10 mins):Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3Health News:American Addiction Centers Named to Inc. 500 List Recognition for Three-Year Sales Growth of 995% 2Health News:Sasha Gets a Butler Mobility Inclined Platform Lift 2
... Haiti , Jan. 19 One week later, ... of delivering aid in the aftermath of the Haiti ... aid is beginning to get through, the impact of the ... combined with a destroyed office and warehouse and the loss ...
... , JACKSONVILLE, Fla. and DES ... Inc. ( www.USPreventiveMedicine.com ) will partner with the Iowa Chronic Care ... not yet eligible for Medicare reduce health risks and live longer, ... equal amounts by a grant/cooperative agreement from the Centers for Disease ...
... PHILADELPHIA , Jan. 19 Independence Blue ... been promoted to chief marketing executive. Taylor will report to ... Independence Blue Cross. , As chief marketing executive, Taylor ... Cross (IBC) and two of the company,s third-party administrators:  Independence ...
... , , PHILADELPHIA , Jan. ... Paul A. Tufano has assumed an expanded role of senior ... continue to report to IBC president and CEO Joseph A. ... counsel since November 1999 when he joined IBC. , ...
... , ... Lindt Chocolate , the world,s leading producer of premium chocolate, announces it ... Autism program. For the second year, Lindt will honor ordinary individuals ... home or community.  The Lindt Unsung Heroes of Autism program is part ...
... Providence, RI New research at Rhode Island Hospital has ... brain tumors which, once diagnosed, offer a poor prognosis and ... naturally-occurring hormone combined with chemotherapy, researchers were able to inhibit ... study and their findings are published in the Journal ...
Cached Medicine News:Health News:Haiti Earthquake: One Week Later, Aid Agencies Facing Challenges 2Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 2Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 3Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 4Health News:Taylor Promoted to Independence Blue Cross Chief Marketing Executive 2Health News:Taylor Promoted to Independence Blue Cross Chief Marketing Executive 3Health News:Independence Blue Cross Announces New, Expanded Role For Key Executive 2Health News:Independence Blue Cross Announces New, Expanded Role For Key Executive 3Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 2Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 3Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 4Health News:Researchers find a treatment for deadly brain tumor 2
...
...
... Bigliani/Flatow shoulder allows for the restoration ... of shoulder replacement surgery. Backed by ... decades of experience, the Bigliani/Flatow Shoulder ... natural shoulder's mobility, balance, and stability ...
... Simplified shoulder replacement system designed ... implantation. Multiple component combinations for ... revision length porous titanium stems. ... of Bi-Polar shell diameters and ...
Medicine Products: